company background image
PFE logo

Pfizer NYSE:PFE Stock Report

Last Price

US$26.10

Market Cap

US$145.8b

7D

1.1%

1Y

-8.9%

Updated

09 Dec, 2024

Data

Company Financials +

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Pfizer Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pfizer
Historical stock prices
Current Share PriceUS$26.10
52 Week HighUS$31.54
52 Week LowUS$24.48
Beta0.59
11 Month Change-2.32%
3 Month Change-12.24%
1 Year Change-8.87%
33 Year Change-52.72%
5 Year Change-33.32%
Change since IPO5,660.01%

Recent News & Updates

Pfizer: Too Cheap To Ignore

Dec 05

Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks

Nov 21

Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer

Nov 15

Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Nov 13
Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Recent updates

Pfizer: Too Cheap To Ignore

Dec 05

Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks

Nov 21

Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer

Nov 15

Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Nov 13
Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings

Pfizer: Discounted For A Reason - But Dividend Story Remains Rich

Nov 08

Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 01
Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed

Oct 29

Pfizer: Activists Clouding A Promising Picture

Oct 21

Pfizer: A Strong Product Pipeline Could Lead To Significant Upside

Oct 08

Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'

Oct 01

There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Sep 23
There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Sep 23

Why Pfizer Investors Should Closely Monitor VAX-31

Sep 05

Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds

Aug 30

Shareholder Returns

PFEUS PharmaceuticalsUS Market
7D1.1%-0.2%0.08%
1Y-8.9%13.2%31.4%

Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.

Return vs Market: PFE underperformed the US Market which returned 31.4% over the past year.

Price Volatility

Is PFE's price volatile compared to industry and market?
PFE volatility
PFE Average Weekly Movement3.2%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: PFE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PFE's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
184988,000Albert Bourlawww.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands.

Pfizer Inc. Fundamentals Summary

How do Pfizer's earnings and revenue compare to its market cap?
PFE fundamental statistics
Market capUS$145.81b
Earnings (TTM)US$4.27b
Revenue (TTM)US$59.38b

34.6x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PFE income statement (TTM)
RevenueUS$59.38b
Cost of RevenueUS$17.94b
Gross ProfitUS$41.43b
Other ExpensesUS$37.16b
EarningsUS$4.27b

Last Reported Earnings

Sep 29, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.75
Gross Margin69.78%
Net Profit Margin7.20%
Debt/Equity Ratio73.4%

How did PFE perform over the long term?

See historical performance and comparison

Dividends

6.4%

Current Dividend Yield

221%

Payout Ratio